Table 1.
Basal clinical characteristics of participants in the study.
| PA | Non-PA | p | |
|---|---|---|---|
| Age (years) | 51.5 ± 13.5 | 47.0 ± 16.3 | 0.45 |
| Male/Female | 6/9 | 5/7 | |
| BMI (kg/m2) | 23.5 ± 2.9 | 30.8 ± 8.1 | 0.01 |
| Systolic blood pressure (mmHg) | 129.2 ± 15.2 | 113.1 ± 11.2 | 0.004 |
| Diastolic blood pressure (mmHg) | 84.3 ± 11.3 | 72.3 ± 15.1 | 0.03 |
| HR (bpm) | 76.6 ± 13.5 | 78.9 ± 10.3 | 0.61 |
| BUN (mg/dL) | 11.2 ± 3.3 | 15.2 ± 5.9 | 0.05 |
| Creatinine (mg/dL) | 0.68 ± 0.11 | 0.89 ± 0.34 | 0.06 |
| Na (mmol/L) | 139.9 ± 1.7 | 139.3 ± 3.0 | 0.50 |
| K (mmol/L) | 3.8 ± 0.3 | 4.0 ± 0.4 | 0.23 |
| Cl (mmol/L) | 106.0 ± 2.0 | 104.4 ± 2.5 | 0.09 |
| eGFR (mL/min/1.73 m2) | 82.7 ± 12.2 | 70.9 ± 24.0 | 0.14 |
| Plasma aldosterone concentration (pg/mL) | 158.9 ± 57.0 | 170.0 ± 84.6 | 0.70 |
| Active renin concentration (pg/mL) | 7.4 ± 19.2 | 28.0 ± 31.2 | 0.06 |
| ARR | 103.2 ± 76.3 | 12.5 ± 9.5 | <0.001 |
| Antihypertensive drugs | |||
| Calcium channel blocker | 10/15 (67%) | 6/12 (50%) | |
| Angiotensin II Receptor Blocker | 0/15 (0%) | 5/12 (42%) | |
| Mineralocorticoid receptor antagonist | 1/15 (7%) | 0/12 (0%) |
Date are shown as average (mean ± SD); BMI: Body mass index, PA: Primary aldosteronism, ARR: Aldosterone-to-Renin Ratio.